# TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

> **NCT01883219** · PHASE2 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
- Stem Cell Transplantation
- Minimal Residual Disease

## Interventions

- **DRUG:** TKIs

## Key facts

- **NCT ID:** NCT01883219
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2016-06
- **Final completion:** 2017-11
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2017-11-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01883219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01883219, "TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT01883219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*